Nanoscope Therapeutics Highlights Optogenetic Therapy Progress at Key Ophthalmology Conferences
Event summary
- Nanoscope Therapeutics will present at Eyecelerator 2026 and the American Academy of Ophthalmology 2026 Annual Meeting, October 8–13, 2026.
- Four-year data from the RESTORE Phase 2b/3 trial of MCO-010 in retinitis pigmentosa will be presented.
- Scientific poster on dry AMD with sonpiretigene isteparvovec optogenetic therapy to be showcased.
- MOGENRY® (MCO-010) under FDA and PMDA review for inherited retinal dystrophies.
The big picture
Nanoscope Therapeutics is positioning itself as a leader in optogenetic gene therapy, leveraging its proprietary MCO technology to address a broad spectrum of retinal degenerative diseases. The company's participation in key ophthalmology conferences underscores its strategic focus on accelerating the development and commercialization of its lead asset, MOGENRY®. With the FDA and PMDA reviews underway, Nanoscope is poised to potentially transform the treatment landscape for patients with inherited retinal dystrophies.
What we're watching
- Regulatory Approval
- Whether the FDA and PMDA will approve MOGENRY® for inherited retinal dystrophies, potentially making it the standard of care.
- Clinical Expansion
- The pace at which Nanoscope can initiate and complete additional Phase 2 and Phase 3 trials for other retinal diseases.
- Market Penetration
- How Nanoscope will position MOGENRY® in a competitive landscape of emerging retinal therapies.
Related topics